Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03445988 · ClinicalTrials.gov registry record · NA
Cognitive Behavioral Therapy and Chronic Pain Self-Management Within the Context of Opioid Reduction: The EMPOWER Study
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 1,462
- Enrollment target
NCT03445988: Completed NA study, sponsored by Stanford University.
NCT03445988 is a NA study that has completed, run by Stanford University. The registered enrollment target is 1,462 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03445988, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,462 participants
- Enrollment target
Study Summary
The proposed study will fill several critical gaps in evidence that are preventing patients and physicians from making informed decisions about their pain care. This project will provide patients taking opioids and physicians with the specific evidence they need to choose the most effective route to pain control, reduced pain interference, opioid reduction, and improved role function, thereby improving patient care. The aims of this study are to (1) reduce or contain prescription opioid use while maintaining pain control and (2) compare the effectiveness of the Chronic Pain Self-Management Program (CPSMP), Cognitive Behavioral Therapy for chronic pain (pain-CBT), and no behavioral treatment within the context of patient-centered collaborative opioid tapering (Taper Only). The acronym EMPOWER stands for Effective Management of Pain and Opioid-Free Ways to Enhance Relief.
Primary Outcome
Opioid tapering success was defined as either: 50% reduction in opioid dose (change in MEDD baseline to 12 months) and no significantly increased pain (≤ 1 point increase in PROMIS pain intensity score from baseline to 12 months), or; no opioid dose increase (baseline MEDD to 12 months) and significant pain relief (≥ 2 points decrease in PROMIS pain intensity score). Pain intensity score: Patient self-reported pain intensity on 11 point (0-10) numerical rating scale where a lower score means mor
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy
- BEHAVIORAL Chronic Pain Self Management Program
- OTHER Taper Only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,462 participants |
| Start Date | 2018-07-24 |
| Est. Completion | 2023-11-06 |
| Phase | NA |
What the finished NCT03445988 record still lists
NCT03445988 is an interventional study that assigns participants to a tested intervention. Its 1,462 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Cognitive Behavioral Therapy is the first listed.
NCT03445988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03445988 about?
NCT03445988 is a clinical study titled "Cognitive Behavioral Therapy and Chronic Pain Self-Management Within the Context of Opioid Reduction: The EMPOWER Study". The proposed study will fill several critical gaps in evidence that are preventing patients and physicians from making informed decisions about their pain care. This project will provide patients taking opioids and physicians with the specific evidence they need to choose the most effective route to...
What is the current status of trial NCT03445988?
This trial is currently completed. It is a NA study. The enrollment target is 1,462 participants. The study started on 2018-07-24. Estimated completion is 2023-11-06.
What interventions are being tested in trial NCT03445988?
The interventions under investigation include: Cognitive Behavioral Therapy (BEHAVIORAL), Chronic Pain Self Management Program (BEHAVIORAL), Taper Only (OTHER).
Who is sponsoring clinical trial NCT03445988?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03445988's enrollment target sits among peer trials
1,462 68th of 2000 higher than 1,933 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI